C-reactive protein and mortality in hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS)

Nephron - Clinical Practice

Volumn 117, Issue 2, 2011, Pages

  Kawaguchi, Takehiko ^a,c   Tong, Lin ^c   Robinson, Bruce M ^c   Sen, Ananda ^d   Fukuhara, Shunichi ^a   Kurokawa, Kiyoshi ^b   Canaud, Bernard ^e   Lameire, Norbert ^f   Port, Friedrich K ^c   Pisoni, Ronald L ^c  

^a KYOTO UNIVERSITY   (Japan)

^b NATIONAL GRADUATE INSTITUTE FOR POLICY STUDIES   (Japan)

^c ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e LAPEYRONIE HOSPITAL   (France)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

C reactive protein; Cardiovascular mortality; Dialysis Outcomes and Practice Patterns Study; Hemodialysis; Inflammatory markers

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; CANADA; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HEALTH CARE FACILITY; HEMODIALYSIS; HUMAN; INFLAMMATION; JAPAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUTRITION; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; RISK; UNITED STATES;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; INTERNATIONALITY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77955520328     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320116     Document Type: Article

References (38)

1. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658.
2. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469-476.
3. Pearson T, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F, Centers for Disease Control and Prevention, American Heart Association: Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
4. Young EW, Goodkin DA, Mapes DL, Port FK, Keen ML, Chen K, Maroni BL, Wolfe RA, Held PJ: The Dialysis Outcomes and Practice Patterns Study (DOPPS): an international hemodialysis study. Kidney Int 2000;57(suppl 74): S74-S81.
5. Pisoni RL, Gillespie BW, Dickinson DM, Chen K, Kutner MH, Wolfe RA: The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. Am J Kidney Dis 2004;44(suppl 2): S7-S15.
6. SAS/STAT User's Guide, Version 8, Volume 2. Cary, SAS Institute, 2000, p 1452.
7. Klein J, Moeschberger M: Survival Analysis Techniques for Censored and Truncated Data. New York, Springer, 1997, pp 416-418.
8. Iseki K, Tozawa M, Yoshi S, Fukiyama K: Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999;14:1956-1960.
9. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-1911.
10. Kaysen GA, Dublin JA, Muller HG, Mitch WE, Rosales LM, Levin NW: Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int 2002;61:2240-2249.
11. Japanese Ministry of Health, Labor and Welfare Web site (in Japanese). http://www.iryohoken. go.jp (accessed September 2009).
12. University of Michigan Department of Pathology Clinical Test Catalog. http://www.pathology.med.umich.edu/handbook/(accessed September 2009).
13. Wang Y, Ripperger J, Fey GH, Samols D, Kordula T, Wetzler M, Van Etten RA, Baumann H: Modulation of hepatic acute phase gene expression by epidermal growth factor and Src protein tyrosine kinases in murine and human hepatic cells. Hepatology 1999;30:682-697.
14. Heinrich PC, Castell J V, Andus T: Interleukin-6 and the acute phase response. Biochem J 1990;265:621-636.
15. Hage FG, Szalai AJ: C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovascular disease risk. J Am Coll Cardiol 2007;50:1115-1122.
16. Wetmore JB, Lovett DH, Hung AM, Cook-Wiens G, Mahnken JD, Sen S, Johansen KL: Associations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patients. Nephrology (Carlton) 2008;13:593-600.
17. Shinohara T, Takahashi N, Yufu K, Anan F, Kakuma T, Hara M, Nakagawa M, Saikawa T, Yoshimatsu H: Role of interleukin-6 levels in cardiovascular autonomic dysfunction in type 2 diabetic patients. Eur J Nucl Med Mol Imaging 2008;35:1616-1623.
18. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D: The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000;342:1-8.
19. Abbott R, Ueshima H, Rodriguez BL, Kadowaki T, Masaki KH, Willcox BJ, Sekikawa A, Kuller LH, Edmundowicz D, Shin C, Kashiwagi A, Nakamura Y, El-Saed A, Okamura T, White R, Curb JD: Coronary artery calcification in Japanese men in Japan and Hawaii. Am J Epidemiol 2007;166:1280-1287.
20. Sekikawa A, Ueshima H, Kadowaki T, El-Saed A, Okamura T, Takamiya T, Kashiwagi A, Edmundowicz D, Murata K, Sutton-Tyrrell K, Maegawa H, Evans RW, Kita Y, Kuller LH: Less subclinical atherosclerosis in Japanese men in Japan than in white men in the United States in the post-World War II birth cohort. Am J Epidemiol 2007;165:617-624.
21. den Elzen WP, van Manen JG, Boeschoten EW, Krediet RT, Dekker FW: The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non-cardiovascular mortality in patients starting with dialysis. Nephrol Dial Transplant 2006;21:1588-1595.
22. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524.
23. Schindler R, Boenisch O, Fischer C, Frei U: Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol 2000;53:452-459.
24. Hoenich NA, Levin R: The implications of water quality in hemodialysis. Semin Dial 2003;16:492-497.
25. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW: Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001;16:2386-2394.
26. Wong JS, Port FK, Hulbert-Shearon TE, Carroll CE, Wolfe RA, Agodoa LY, Daugirdas JT: Survival advantage in Asian American endrenal disease patients. Kidney Int 1999;55:2515-2523.
27. Torun D, Micozkadioglu H, Torun N, Ozelsancak R, Sezer S, Adam FU, Ozdemir FN, Haberal M: Increased body mass index is not a reliable marker of good nutrition in hemodialysis patients. Ren Fail 2007;29:487-493.
28. Owen WF, Lowrie EG: C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998;54:627-636.
29. Pifer TB, McCullough KP, Port FK, Goodkin DA, Maroni BJ, Held PJ, Young EW: Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002;62:2238-2245.
30. Hsu SP, Pai MF, Peng YS, Chiang CK, Ho TI, Hung KY: Serum uric acid levels show a 'J-shaped' association with all-cause mortality in haemodialysis patients. Nephrol Dial Transplant 2004;19:457-462.
31. Rich MW: Uric acid: is it a risk factor for cardiovascular disease? Am J Cardiol 2000;85:1018-1021.
32. Caravaca F, Martín MV, Barroso S, Cancho B, Arrobas M, Luna E, Sánchez-Casado E: Serum uric acid and C-reactive protein levels in patients with chronic kidney disease (in Spanish). Nefrologia 2005;25:645-654.
33. Payne RB, Little AJ, Williams RB, Milner JR: Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973;4:643-646.
34. Movilli E, Brunori G, Camerini C, Vizzardi V, Gaggia P, Cassamali S, Scolari F, Parrinello G, Cancarini GC: The kind of vascular access influences the baseline inflammatory status and epoetin response in chronic hemodialysis patients. Blood Purif 2006;24:387-393.
35. Japanese Society of Dialysis Therapy Web site (in Japanese). http://www.jsdt.or.jp/(accessed September 2009).
36. Stenvinkel P: Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant 2002;17(suppl 8):33-38.
37. Albert MA, Ridker PM: C-reactive protein as a risk predictor: do race/ethnicity and gender make a difference? Circulation 2006;114:2619-2626.
38. Stenvinkel P, Wanner C, Metzger T, Heimbürger O, Mallamaci F, Tripepi G, Malatino L, Zoccali C: Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 2002;62:1791-1798.